Overview

Pembrolizumab for Newly Diagnosed Glioblastoma

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The study explores the addition of pembrolizumab to temozolomide-based radiotherapy in patients with newly diagnosed glioblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Zurich
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab